SELLAS Life Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell SLS and other ETFs, options, and stocks.

About SLS

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. 

CEO
Angelos M. Stergiou
CEOAngelos M. Stergiou
Employees
13
Employees13
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2006
Founded2006
Employees
13
Employees13

SLS Key Statistics

Market cap
2.28B
Market cap2.28B
Price-Earnings ratio
-53.06
Price-Earnings ratio-53.06
Dividend yield
—
Dividend yield—
Average volume
4.60M
Average volume4.60M
High today
$11.34
High today$11.34
Low today
$10.71
Low today$10.71
Open price
$11.18
Open price$11.18
Volume
4.21M
Volume4.21M
52 Week high
$15.88
52 Week high$15.88
52 Week low
$1.39
52 Week low$1.39

Stock Snapshot

SELLAS Life Sciences(SLS) stock is priced at $11.24, giving the company a market capitalization of 2.28B. It carries a P/E multiple of -53.06.

During the trading session on 2026-10-08, SELLAS Life Sciences(SLS) shares reached a daily high of $11.34 and a low of $10.71. At a current price of $11.24, the stock is +4.9% higher than the low and still -0.9% under the high.

Trading activity shows a volume of 4.21M, compared to an average daily volume of 4.6M.

Over the past 52 weeks, SELLAS Life Sciences(SLS) stock has traded between a high of $15.88 and a low of $1.39.

Over the past 52 weeks, SELLAS Life Sciences(SLS) stock has traded between a high of $15.88 and a low of $1.39.

SLS News

Simply Wall St 5d
SELLAS Life Sciences Group Following New SLS009 Data Is The Upside Still Priced In

Advertisement Why New SLS009 Data Matters For SELLAS Life Sciences Group SELLAS Life Sciences Group (SLS) is in focus after releasing preclinical results for...

SELLAS Life Sciences Group Following New SLS009 Data Is The Upside Still Priced In
Simply Wall St 7d
Can SELLAS Stock Gain From Resistant Pancreatic Cancer Data

SELLAS Life Sciences Group reported preclinical data on SLS009 in MYC amplified, RAS inhibitor resistant pancreatic ductal adenocarcinoma organoid models, showi...

Can SELLAS Stock Gain From Resistant Pancreatic Cancer Data

People also own

Based on the portfolios of people who own SLS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.